Compare Biogen Inc (BIIB) vs Dollar Tree, Inc. (DLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Dollar Tree, Inc. — how do they compare? Biogen Inc trades at $192.5 (market cap $28.34B), while Dollar Tree, Inc. trades at $125 (market cap $23.94B). The key difference: Biogen Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| BIIB | DLTR | |
|---|---|---|
Market Cap | $28.34B | $23.94B |
Sector | Health | Health |
52-Week High | $216.63 | $141.21 |
52-Week Low | $122.68 | $85.04 |
Enterprise Value | $30.62B | $30.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Dollar Tree (DLTR) trades at $126.38, up 1.18% today, with a bullish technical signal and strong recent earnings beats. The company's fundamentals show a net loss in 2025 but improving cash flow and a $2.5 billion share repurchase authorization signal confidence. Analyst consensus is a Buy with a $131 price target, though valuation ratios like P/E of 20.29 and P/B of 6.93 reflect moderate pricing.
The outlook is positive due to earnings momentum and cost controls, but risks include traffic softness and tariff pressures. Upside potential exists if margin gains and multi-price strategy sustain growth, yet investors must weigh high debt and competitive headwinds against cash flow strength and institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →
